{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:45:55Z","timestamp":1791305155180,"version":"4.3.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U24-CA076518"],"award-info":[{"award-number":["U24-CA076518"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and\u00a0Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"crossref","award":["5U10HL069294"],"award-info":[{"award-number":["5U10HL069294"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NCI"},{"DOI":"10.13039\/100000102","name":"Health Resources and Services Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000006","name":"Office of Naval Research","doi-asserted-by":"publisher","award":["N00014-13-1-0039"],"award-info":[{"award-number":["N00014-13-1-0039"]}],"id":[{"id":"10.13039\/100000006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000006","name":"Office of Naval Research","doi-asserted-by":"publisher","award":["N00014-14-1-0028"],"award-info":[{"award-number":["N00014-14-1-0028"]}],"id":[{"id":"10.13039\/100000006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010535","name":"Actinium Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010535","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010299","name":"Allos Therapeutics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010299","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.bbmt.2015.02.005","type":"journal-article","created":{"date-parts":[[2015,2,13]],"date-time":"2015-02-13T23:57:45Z","timestamp":1423871865000},"page":"1046-1053","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":148,"title":["Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation"],"prefix":"10.1016","volume":"21","author":[{"given":"Yi-Bin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent R.","family":"Logan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6rg\u00fcn","family":"Akpek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud D.","family":"Aljurf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Artz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher N.","family":"Bredeson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth R.","family":"Cooke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent T.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillard M.","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F.","family":"Olsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael","family":"Saber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip L.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo C.","family":"Pasquini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2015.02.005_bib1","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1634\/theoncologist.2011-0177","article-title":"Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin's lymphoma","volume":"17","author":"Colpo","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.bbmt.2015.02.005_bib2","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1634\/theoncologist.2009-0162","article-title":"Controversies in the treatment of lymphoma with autologous transplantation","volume":"14","author":"Moskowitz","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.bbmt.2015.02.005_bib3","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1586\/ehm.09.24","article-title":"Transplantation for non-Hodgkin lymphoma","volume":"2","author":"Nademanee","year":"2009","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.bbmt.2015.02.005_bib4","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/sj.bmt.1705744","article-title":"Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road?","volume":"40","author":"Fernandez","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.02.005_bib5","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1378\/chest.10-2889","article-title":"Risk factors and outcome of pulmonary complications after autologous hematopoietic stem cell transplant","volume":"141","author":"Afessa","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.bbmt.2015.02.005_bib6","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/sj.bmt.1704141","article-title":"Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer","volume":"31","author":"Wong","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.02.005_bib7","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/sj.bmt.1705951","article-title":"Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma","volume":"41","author":"Benekli","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.02.005_bib8","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/blood.V89.3.801","article-title":"High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices","volume":"89","author":"Horning","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.02.005_bib9","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1182\/blood.V85.5.1381.bloodjournal8551381","volume":"85","author":"Nademanee","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.02.005_bib10","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1080\/10428190500527769","article-title":"Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation","volume":"47","author":"Puig","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2015.02.005_bib11","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1200\/JCO.1991.9.10.1871","article-title":"Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease","volume":"9","author":"Reece","year":"1991","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.02.005_bib12","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.3109\/10428194.2011.645208","article-title":"Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant","volume":"53","author":"Lane","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2015.02.005_bib13","first-page":"87","article-title":"2010 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders","author":"Pasquini","year":"2010","journal-title":"Clin Transpl"},{"key":"10.1016\/j.bbmt.2015.02.005_bib14","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/sj.bmt.1700913","article-title":"BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors","volume":"20","author":"Caballero","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.02.005_bib15","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1200\/JCO.1990.8.4.648","article-title":"Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study","volume":"8","author":"Wheeler","year":"1990","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.02.005_bib16","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.bbmt.2009.07.014","article-title":"Busulfan and cyclophosphamide (Bu\/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience","volume":"15","author":"Ulrickson","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.02.005_bib17","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2015.02.005_bib18","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1200\/JCO.2012.45.9453","volume":"31","author":"Vose","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.02.005_bib19","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.bbmt.2007.06.003","article-title":"Late effects in survivors of Hodgkin and non-Hodgkin lymphoma treated with autologous hematopoietic cell transplantation: a report from the bone marrow transplant survivor study","volume":"13","author":"Majhail","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.02.005_bib20","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/sj.bmt.1704393","article-title":"Pulmonary function after autologous bone marrow transplantation in children: a long-term prospective study","volume":"33","author":"Frisk","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.02.005_bib21","first-page":"167","article-title":"Autologous stem cell transplantation for high-risk Hodgkin's disease: improvement over time and impact of conditioning regimen","volume":"85","author":"Subira","year":"2000","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2015.02.005_bib22","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1200\/JCO.2001.19.5.1395","article-title":"Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas\/Transplante Autologo de Medula Osea Spanish Cooperative Group","volume":"19","author":"Sureda","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.02.005_bib23","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/annonc\/mdg008","article-title":"High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group","volume":"14","author":"Caballero","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2015.02.005_bib24","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/sj.bmt.1703179","article-title":"Autologous stem cell transplantation for non-Hodgkin's lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens","volume":"28","author":"Gutierrez-Delgado","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.02.005_bib25","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/sj.bmt.1702795","article-title":"Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens","volume":"27","author":"Salar","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.02.005_bib26","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.clml.2013.03.009","article-title":"Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma","volume":"13","author":"William","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.bbmt.2015.02.005_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2013.12.259","article-title":"Matched pair comparison of busulfan\/cyclophosphamide\/etoposide (BuCyE) to carmustine\/etoposide\/cytarabine\/melphalan (BEAM) conditioning regimen prior to autologous hematopoietic cell transplantation (autoHCT) for lymphoma","author":"Pasquini","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.02.005_bib28","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2011-04-351924","article-title":"BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant\/relapsed lymphoma patients","volume":"118","author":"Visani","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.02.005_bib29","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1200\/JCO.2005.05.117","article-title":"Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma","volume":"23","author":"Vose","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.02.005_bib30","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.bbmt.2012.08.013","article-title":"Phase II trial of 131-Iodine tositumomab with high-dose chemotherapy and autologous stem cell transplantation for relapsed diffuse large B cell lymphoma","volume":"19","author":"Vose","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.02.005_bib31","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.bbmt.2012.10.029","article-title":"Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome","volume":"19","author":"Nieto","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.02.005_bib32","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3109\/10428194.2013.806659","article-title":"Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed\/refractory Hodgkin lymphoma","volume":"55","author":"Bains","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2015.02.005_bib33","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.bbmt.2011.07.016","article-title":"Matched-cohort analysis of autologous hematopoietic cell transplantation with radioimmunotherapy versus total body irradiation-based conditioning for poor-risk diffuse large cell lymphoma","volume":"18","author":"Krishnan","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.02.005_bib34","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.bbmt.2014.01.004","article-title":"Phase I\/II study of VELCADE(R)-BEAM (V-BEAM) and autologous hematopoietic stem cell transplantation (ASCT) for relapsed indolent non-Hodgkin lymphoma (NHL), transformed, or mantle cell lymphoma (MCL)","volume":"20","author":"William","year":"2014","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879115001123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879115001123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:51:25Z","timestamp":1761058285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879115001123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S1083879115001123"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.02.005","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}